Direct generation of induced pluripotent stem cells from human nonmobilized blood

A Kunisato, M Wakatsuki, H Shinba, T Ota… - Stem cells and …, 2011 - liebertpub.com
A Kunisato, M Wakatsuki, H Shinba, T Ota, I Ishida, K Nagao
Stem cells and development, 2011liebertpub.com
The use of induced pluripotent stem cells (iPSCs) is an exciting frontier in the study and
treatment of human diseases through the generation of specific cell types. Here we show the
derivation of iPSCs from human nonmobilized peripheral blood (PB) and bone marrow (BM)
mononuclear cells (MNCs) by retroviral transduction of OCT3/4, SOX2, KLF4, and c-MYC.
The PB-and BM-derived iPSCs were quite similar to human embryonic stem cells with
regard to morphology, expression of surface antigens and pluripotency-associated …
The use of induced pluripotent stem cells (iPSCs) is an exciting frontier in the study and treatment of human diseases through the generation of specific cell types. Here we show the derivation of iPSCs from human nonmobilized peripheral blood (PB) and bone marrow (BM) mononuclear cells (MNCs) by retroviral transduction of OCT3/4, SOX2, KLF4, and c-MYC. The PB- and BM-derived iPSCs were quite similar to human embryonic stem cells with regard to morphology, expression of surface antigens and pluripotency-associated transcription factors, global gene expression profiles, and differentiation potential in vitro and in vivo. Infected PB and BM MNCs gave rise to iPSCs in the presence of several cytokines, although transduction efficiencies were not high. We found that 5 × 105 PB MNCs, which corresponds to less than 1 mL of PB, was enough for the generation of several iPSC colonies. Generation of iPSCs from MNCs of nonmobilized PB, with its relative efficiency and ease of harvesting, could enable the therapeutic use of patient-specific pluripotent stem cells.
Mary Ann Liebert